查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
分子生物學用酵素、套件、試劑市場規模，佔有率，趨勢分析:各產品，各用途，各終端用戶，各地區展望，競爭策略，至2030年的各市場區隔預測
市場調查報告書
商品編碼
1089966

分子生物學用酵素、套件、試劑市場規模，佔有率，趨勢分析:各產品，各用途，各終端用戶，各地區展望，競爭策略，至2030年的各市場區隔預測

Molecular Biology Enzymes & Kits & Reagents Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 256 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球分子生物學用酵素、套件、試劑的市場規模，預計今後以13.6％的年複合成長率擴大，至2030年達到482億1,000萬美元。研究的活躍，投資，基因計劃增加，生命科學產業上技術的進步，遺傳性疾病的發生率上升等，成為市場擴大的要素。

本報告提供全球分子生物學用酵素、套件、試劑市場相關調查，市場概要，以及各產品，各用途，各終端用戶，各地區的趨勢，及加入此市場的主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 成長要素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • COVID-19分子生物學用酵素、套件、試劑市場的影響

第5章 市場變數及預測

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 熱圖分析

第6章 分子生物學用酵素、套件、試劑市場，各產品，2019年～2030年(100萬美元)

  • 套件和試劑
  • 酵素
  • 聚合酵素
  • 連接酶
  • 限制酵素
  • 逆轉錄酵素
  • 其他

第7章 分子生物學用酵素、套件、試劑市場，各用途，2019年～2030年(100萬美元)

  • PCR
  • 定序
  • 基因複製
  • 表觀遺傳學
  • 限制消化
  • 合成生物學
  • 其他

第8章 分子生物學用酵素、套件、試劑市場，各終端用戶，2019年～2030年(100萬美元)

  • 學術研究機關
  • 製藥公司、生物科技企業
  • 醫院、診斷中心
  • 其他

第9章 分子生物學用酵素、套件、試劑市場，各地區，2019年～2030年(100萬美元)

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第10章 企業簡介

  • ADS Biotec Inc.
  • Agilent
  • Aldevron
  • Bio Basic
  • Bio-Rad Laboratories Inc
  • Genekam Biotechnology
  • Goldsite Diagnostics Inc.
  • Hangzhou Matridx Biotechnology Co. Ltd.
  • Illumina
  • Integrated DNA Technologies, Inc.
  • Jena Bioscience
  • LGC Biosearch Technologies
  • Lucigen Corporation
  • Merck
  • MoBiTec GmbH
  • Molecular Biology Resources
  • New England Biolabs
  • NZYTech
  • Promega
  • QIAGEN
  • Randox
  • Roche
  • Takara Bio
  • Thermo Fisher
  • Zymo Research Corporation
簡介目錄
Product Code: BIOT2232

Global Molecular Biology Enzymes & Kits & Reagents Market projected to be worth USD 48.21 billion by 2030.

According to SPER Market Research, the Molecular Biology Enzymes & Kits & Reagents Market estimated to reach USD 48.21 billion by 2030 with a CAGR of 13.6%. Amplified research, investments, increasing number of genome projects, technological advancement in the life science industry, and growing incidence of genetic disorders; are the fuels for the escalation of the market.

Impact of COVID-19 on the Molecular Biology Enzymes & Kits & Reagents Market

The outbreak of COVID-19 gives a positive impact to the expansion Molecular Biology Enzymes & Kits & Reagents Market.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Material, By Technique, By Application, By End-Users, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: ADS Biotec Inc., Agilent, Aldevron, Bio Basic, Bio-Rad Laboratories, Inc.¸Genekam Biotechnology, Goldsite Diagnostics Inc., Hangzhou Matridx Biotechnology Co. Ltd., Illumina, Integrated DNA Technologies, Inc., Jena Bioscience, LGC Biosearch Technologies, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, New England Biolabs, NZYTech, Promega, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation

Driver: increasing number of genome projects

The increasing numeral of genome projects globally, tied with dipping genetic analysis costs; leads to advancement in research in diverse fields like; personalized medicine, microbial genetic, disease treatment. This research need the use of molecular biology enzymes and reagents, consequently impel the expansion of this molecular biology enzymes and kits & reagents market.

Restraints: restricted reimbursements for genetic testing

The inflexible reimbursement policy is the restraints to this market.

Opportunity: Research & Development investments offer significant opportunities for the market

Increase in the funds & grants from the government, advancement in the genomic technological facade, investments in research & development have vast opportunities for this market.

Molecular Biology Enzymes & Kits & Reagents Market, By Product:

Based on the Product, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Kits & Reagents, Enzymes, Polymerases, Ligases, Restriction Endonucleases, Reverse Transcriptases, Other Enzymes.

Molecular Biology Enzymes & Kits & Reagents Market, By Application:

Based on the Application, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology, Other Applications.

Molecular Biology Enzymes & Kits & Reagents Market, By End User:

Based on the End-Users, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Academic & Research Institutes, Pharmaceutical & Biotechnology companies, Hospitals & Diagnostic Centers, Other End Users.

Molecular Biology Enzymes & Kits & Reagents Market, By Region:

North America dominates the biggest share of this market; this is due to the increase in funding of translational and clinical research, increasing the figure of pharmaceutical and biotechnology companies, rising investments in research projects in Canada favourable reimbursement scenario.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Molecular Biology Enzymes & Kits & Reagents Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Molecular Biology Enzymes & Kits & Reagents Market, By Product, 2019-2030 (USD Million)

  • 6.1. Kits & Reagents
  • 6.2. Enzymes
  • 6.3. Polymerases
  • 6.4. Ligases
  • 6.5. Restriction Endonucleases
  • 6.6. Reverse Transcriptases
  • 6.7. Other Enzymes

7. Molecular Biology Enzymes & Kits & Reagents Market, By Application, 2019-2030 (USD Million)

  • 7.1. PCR
  • 7.2. Sequencing
  • 7.3. Cloning
  • 7.4. Epigenetics
  • 7.5. Restriction Digestion
  • 7.6. Synthetic Biology
  • 7.7. Other Applications

8. Molecular Biology Enzymes & Kits & Reagents Market, By End User, 2019-2030 (USD Million)

  • 8.1. Academic & Research Institutes
  • 8.2. Pharmaceutical & Biotechnology companies
  • 8.3. Hospitals & Diagnostic Centers
  • 8.4. Other End Users

9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. ADS Biotec Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Aldevron
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Bio Basic
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Bio-Rad Laboratories Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Genekam Biotechnology
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Goldsite Diagnostics Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hangzhou Matridx Biotechnology Co. Ltd.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Illumina
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Integrated DNA Technologies, Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Jena Bioscience
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. LGC Biosearch Technologies
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Lucigen Corporation
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Merck
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. MoBiTec GmbH
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Molecular Biology Resources
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. New England Biolabs
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. NZYTech
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Promega
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. QIAGEN
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Randox
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Roche
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takara Bio
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. Thermo Fisher
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments
  • 10.25. Zymo Research Corporation
    • 10.25.1. Company details
    • 10.25.2. Financial outlook
    • 10.25.3. Product summary
    • 10.25.4. Recent developments

9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)

  • 9.1. North America
    • 9.1.1. United States
    • 9.1.2. Canada
    • 9.1.3. Mexico
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. United Kingdom
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. Japan
    • 9.3.3. India
    • 9.3.4. Australia
    • 9.3.5. South Korea
    • 9.3.6. Rest of Asia-Pacific
  • 9.4. South America
    • 9.4.1. Brazil
    • 9.4.2. Argentina
    • 9.4.3. Rest of South America
  • 9.5. Middle East & Africa
    • 9.5.1. Kingdom of Saudi Arabia
    • 9.5.2. United Arab Emirates
    • 9.5.3. Rest of Middle East & Africa

10. Company Profiles

  • 10.1. ADS Biotec Inc.
    • 10.1.1. Company details
    • 10.1.2. Financial outlook
    • 10.1.3. Product summary
    • 10.1.4. Recent developments
  • 10.2. Agilent
    • 10.2.1. Company details
    • 10.2.2. Financial outlook
    • 10.2.3. Product summary
    • 10.2.4. Recent developments
  • 10.3. Aldevron
    • 10.3.1. Company details
    • 10.3.2. Financial outlook
    • 10.3.3. Product summary
    • 10.3.4. Recent developments
  • 10.4. Bio Basic
    • 10.4.1. Company details
    • 10.4.2. Financial outlook
    • 10.4.3. Product summary
    • 10.4.4. Recent developments
  • 10.5. Bio-Rad Laboratories Inc.
    • 10.5.1. Company details
    • 10.5.2. Financial outlook
    • 10.5.3. Product summary
    • 10.5.4. Recent developments
  • 10.6. Genekam Biotechnology
    • 10.6.1. Company details
    • 10.6.2. Financial outlook
    • 10.6.3. Product summary
    • 10.6.4. Recent developments
  • 10.7. Goldsite Diagnostics Inc.
    • 10.7.1. Company details
    • 10.7.2. Financial outlook
    • 10.7.3. Product summary
    • 10.7.4. Recent developments
  • 10.8. Hangzhou Matridx Biotechnology Co. Ltd.
    • 10.8.1. Company details
    • 10.8.2. Financial outlook
    • 10.8.3. Product summary
    • 10.8.4. Recent developments
  • 10.9. Illumina
    • 10.9.1. Company details
    • 10.9.2. Financial outlook
    • 10.9.3. Product summary
    • 10.9.4. Recent developments
  • 10.10. Integrated DNA Technologies, Inc.
    • 10.10.1. Company details
    • 10.10.2. Financial outlook
    • 10.10.3. Product summary
    • 10.10.4. Recent developments
  • 10.11. Jena Bioscience
    • 10.11.1. Company details
    • 10.11.2. Financial outlook
    • 10.11.3. Product summary
    • 10.11.4. Recent developments
  • 10.12. LGC Biosearch Technologies
    • 10.12.1. Company details
    • 10.12.2. Financial outlook
    • 10.12.3. Product summary
    • 10.12.4. Recent developments
  • 10.13. Lucigen Corporation
    • 10.13.1. Company details
    • 10.13.2. Financial outlook
    • 10.13.3. Product summary
    • 10.13.4. Recent developments
  • 10.14. Merck
    • 10.14.1. Company details
    • 10.14.2. Financial outlook
    • 10.14.3. Product summary
    • 10.14.4. Recent developments
  • 10.15. MoBiTec GmbH
    • 10.15.1. Company details
    • 10.15.2. Financial outlook
    • 10.15.3. Product summary
    • 10.15.4. Recent developments
  • 10.16. Molecular Biology Resources
    • 10.16.1. Company details
    • 10.16.2. Financial outlook
    • 10.16.3. Product summary
    • 10.16.4. Recent developments
  • 10.17. New England Biolabs
    • 10.17.1. Company details
    • 10.17.2. Financial outlook
    • 10.17.3. Product summary
    • 10.17.4. Recent developments
  • 10.18. NZYTech
    • 10.18.1. Company details
    • 10.18.2. Financial outlook
    • 10.18.3. Product summary
    • 10.18.4. Recent developments
  • 10.19. Promega
    • 10.19.1. Company details
    • 10.19.2. Financial outlook
    • 10.19.3. Product summary
    • 10.19.4. Recent developments
  • 10.20. QIAGEN
    • 10.20.1. Company details
    • 10.20.2. Financial outlook
    • 10.20.3. Product summary
    • 10.20.4. Recent developments
  • 10.21. Randox
    • 10.21.1. Company details
    • 10.21.2. Financial outlook
    • 10.21.3. Product summary
    • 10.21.4. Recent developments
  • 10.22. Roche
    • 10.22.1. Company details
    • 10.22.2. Financial outlook
    • 10.22.3. Product summary
    • 10.22.4. Recent developments
  • 10.23. Takara Bio
    • 10.23.1. Company details
    • 10.23.2. Financial outlook
    • 10.23.3. Product summary
    • 10.23.4. Recent developments
  • 10.24. Thermo Fisher
    • 10.24.1. Company details
    • 10.24.2. Financial outlook
    • 10.24.3. Product summary
    • 10.24.4. Recent developments
  • 10.25. Zymo Research Corporation
    • 10.25.1. Company details
    • 10.25.2. Financial outlook
    • 10.25.3. Product summary
    • 10.25.4. Recent developments